Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Policy / Regulatory

Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement

Fineline Cube May 22, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in...

Company

Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase

Fineline Cube May 22, 2023

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...

Company Drug

Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy

Fineline Cube May 19, 2023

US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...

Company Deals

MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange

Fineline Cube May 19, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin...

Company Deals

Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy

Fineline Cube May 19, 2023

US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...

Company Deals

Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal

Fineline Cube May 19, 2023

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...

Company Deals

International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements

Fineline Cube May 19, 2023

The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development...

Company Medical Device

MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System

Fineline Cube May 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches

Fineline Cube May 19, 2023

A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...

Company Deals

Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope

Fineline Cube May 19, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US...

Company Drug

Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome

Fineline Cube May 19, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....

Company Deals

Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution

Fineline Cube May 19, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Drug

FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial

Fineline Cube May 19, 2023

US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...

Company

GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang

Fineline Cube May 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the...

Company Drug

NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment

Fineline Cube May 18, 2023

Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...

Company Drug

Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101

Fineline Cube May 18, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...

Company Drug

Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study

Fineline Cube May 18, 2023

Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...

Company Drug

BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment

Fineline Cube May 18, 2023

BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...

Company Drug

WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants

Fineline Cube May 18, 2023

Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...

Company Drug

CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer

Fineline Cube May 18, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Posts pagination

1 … 576 577 578 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.